WO2003061700A1 - Medicaments servant au traitement de nephropathies chroniques - Google Patents
Medicaments servant au traitement de nephropathies chroniques Download PDFInfo
- Publication number
- WO2003061700A1 WO2003061700A1 PCT/JP2003/000675 JP0300675W WO03061700A1 WO 2003061700 A1 WO2003061700 A1 WO 2003061700A1 JP 0300675 W JP0300675 W JP 0300675W WO 03061700 A1 WO03061700 A1 WO 03061700A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- group
- chronic kidney
- ncx1
- day
- kidney disease
- Prior art date
Links
- 208000020832 chronic kidney disease Diseases 0.000 title claims abstract description 17
- 150000001875 compounds Chemical class 0.000 claims abstract description 18
- 239000004480 active ingredient Substances 0.000 claims abstract description 7
- 230000002401 inhibitory effect Effects 0.000 claims abstract description 7
- 238000000034 method Methods 0.000 claims description 17
- 108010067207 sodium-calcium exchanger 1 Proteins 0.000 claims description 16
- 102100035088 Sodium/calcium exchanger 1 Human genes 0.000 claims description 15
- 108010078791 Carrier Proteins Proteins 0.000 claims description 12
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 11
- 125000003545 alkoxy group Chemical group 0.000 claims description 9
- 239000003814 drug Substances 0.000 claims description 9
- 229940124597 therapeutic agent Drugs 0.000 claims description 8
- 125000005843 halogen group Chemical group 0.000 claims description 7
- 210000003734 kidney Anatomy 0.000 claims description 7
- 150000003839 salts Chemical class 0.000 claims description 5
- NMFFUUFPJJOWHK-UHFFFAOYSA-N 2-phenoxyaniline Chemical class NC1=CC=CC=C1OC1=CC=CC=C1 NMFFUUFPJJOWHK-UHFFFAOYSA-N 0.000 claims description 2
- 230000001684 chronic effect Effects 0.000 claims 1
- 239000011575 calcium Substances 0.000 description 27
- YSUBLPUJDOWYDP-UHFFFAOYSA-N 2-[4-[(2,5-difluorophenyl)methoxy]phenoxy]-5-ethoxyaniline Chemical compound NC1=CC(OCC)=CC=C1OC(C=C1)=CC=C1OCC1=CC(F)=CC=C1F YSUBLPUJDOWYDP-UHFFFAOYSA-N 0.000 description 19
- 241000700159 Rattus Species 0.000 description 13
- 239000000872 buffer Substances 0.000 description 13
- 230000000694 effects Effects 0.000 description 13
- -1 for example Chemical group 0.000 description 13
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 12
- 239000012528 membrane Substances 0.000 description 10
- 108010088751 Albumins Proteins 0.000 description 9
- 102000009027 Albumins Human genes 0.000 description 9
- 239000000203 mixture Substances 0.000 description 9
- 108090000623 proteins and genes Proteins 0.000 description 9
- 102000004169 proteins and genes Human genes 0.000 description 9
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- 230000002485 urinary effect Effects 0.000 description 7
- 125000000217 alkyl group Chemical group 0.000 description 6
- 210000004556 brain Anatomy 0.000 description 6
- 230000029142 excretion Effects 0.000 description 6
- 238000005259 measurement Methods 0.000 description 6
- 239000011780 sodium chloride Substances 0.000 description 6
- 239000002904 solvent Substances 0.000 description 6
- 210000002700 urine Anatomy 0.000 description 6
- 229910052791 calcium Inorganic materials 0.000 description 5
- 239000008187 granular material Substances 0.000 description 5
- 239000003112 inhibitor Substances 0.000 description 5
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 5
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 4
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 4
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 4
- 229930006000 Sucrose Natural products 0.000 description 4
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 4
- 230000003185 calcium uptake Effects 0.000 description 4
- 206010012601 diabetes mellitus Diseases 0.000 description 4
- 235000005911 diet Nutrition 0.000 description 4
- 230000037213 diet Effects 0.000 description 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 4
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 4
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 4
- 239000008101 lactose Substances 0.000 description 4
- 235000019359 magnesium stearate Nutrition 0.000 description 4
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 description 4
- GYNAVKULVOETAD-UHFFFAOYSA-N n-phenoxyaniline Chemical class C=1C=CC=CC=1NOC1=CC=CC=C1 GYNAVKULVOETAD-UHFFFAOYSA-N 0.000 description 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 4
- 239000005720 sucrose Substances 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- GKWLIQDHWRWNRS-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC(N)(CO)CO.OCCN1CCN(CCS(O)(=O)=O)CC1 GKWLIQDHWRWNRS-UHFFFAOYSA-N 0.000 description 3
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 3
- 229920002261 Corn starch Polymers 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- VJHCJDRQFCCTHL-UHFFFAOYSA-N acetic acid 2,3,4,5,6-pentahydroxyhexanal Chemical compound CC(O)=O.OCC(O)C(O)C(O)C(O)C=O VJHCJDRQFCCTHL-UHFFFAOYSA-N 0.000 description 3
- 125000004423 acyloxy group Chemical group 0.000 description 3
- 125000003277 amino group Chemical group 0.000 description 3
- 125000004432 carbon atom Chemical group C* 0.000 description 3
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 3
- 229950008138 carmellose Drugs 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 125000001309 chloro group Chemical group Cl* 0.000 description 3
- 208000022831 chronic renal failure syndrome Diseases 0.000 description 3
- 239000011248 coating agent Substances 0.000 description 3
- 239000008120 corn starch Substances 0.000 description 3
- 229940099112 cornstarch Drugs 0.000 description 3
- 125000004093 cyano group Chemical group *C#N 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 description 3
- 125000001153 fluoro group Chemical group F* 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 206010061989 glomerulosclerosis Diseases 0.000 description 3
- 238000005469 granulation Methods 0.000 description 3
- 230000003179 granulation Effects 0.000 description 3
- 210000002216 heart Anatomy 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 3
- 230000002107 myocardial effect Effects 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 102000005962 receptors Human genes 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- 125000006828 (C2-C7) alkoxycarbonyl group Chemical group 0.000 description 2
- ZIIUUSVHCHPIQD-UHFFFAOYSA-N 2,4,6-trimethyl-N-[3-(trifluoromethyl)phenyl]benzenesulfonamide Chemical compound CC1=CC(C)=CC(C)=C1S(=O)(=O)NC1=CC=CC(C(F)(F)F)=C1 ZIIUUSVHCHPIQD-UHFFFAOYSA-N 0.000 description 2
- MEAAWTRWNWSLPF-UHFFFAOYSA-N 2-phenoxypyridine Chemical class C=1C=CC=NC=1OC1=CC=CC=C1 MEAAWTRWNWSLPF-UHFFFAOYSA-N 0.000 description 2
- 241000282465 Canis Species 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- 208000007342 Diabetic Nephropathies Diseases 0.000 description 2
- 206010018367 Glomerulonephritis chronic Diseases 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 101001030470 Homo sapiens Sodium/calcium exchanger 2 Proteins 0.000 description 2
- 101000588943 Homo sapiens Sodium/calcium exchanger 3 Proteins 0.000 description 2
- 102000003960 Ligases Human genes 0.000 description 2
- 108090000364 Ligases Proteins 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 2
- 239000000020 Nitrocellulose Substances 0.000 description 2
- 102000015439 Phospholipases Human genes 0.000 description 2
- 108010064785 Phospholipases Proteins 0.000 description 2
- 102100038538 Sodium/calcium exchanger 2 Human genes 0.000 description 2
- 102100032576 Sodium/calcium exchanger 3 Human genes 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 125000003118 aryl group Chemical group 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 230000002490 cerebral effect Effects 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 230000008602 contraction Effects 0.000 description 2
- 125000004122 cyclic group Chemical group 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 208000033679 diabetic kidney disease Diseases 0.000 description 2
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 description 2
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 229960001031 glucose Drugs 0.000 description 2
- 235000001727 glucose Nutrition 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- 210000000231 kidney cortex Anatomy 0.000 description 2
- 230000003907 kidney function Effects 0.000 description 2
- 229960001375 lactose Drugs 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 238000000691 measurement method Methods 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 2
- 239000008108 microcrystalline cellulose Substances 0.000 description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 description 2
- 210000001589 microsome Anatomy 0.000 description 2
- 210000004165 myocardium Anatomy 0.000 description 2
- 229920001220 nitrocellulos Polymers 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 2
- 125000002572 propoxy group Chemical group [*]OC([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 210000002460 smooth muscle Anatomy 0.000 description 2
- 239000012089 stop solution Substances 0.000 description 2
- 125000001424 substituent group Chemical group 0.000 description 2
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- 239000001763 2-hydroxyethyl(trimethyl)azanium Substances 0.000 description 1
- 125000004493 2-methylbut-1-yl group Chemical group CC(C*)CC 0.000 description 1
- 125000003542 3-methylbutan-2-yl group Chemical group [H]C([H])([H])C([H])(*)C([H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 102000009346 Adenosine receptors Human genes 0.000 description 1
- 108050000203 Adenosine receptors Proteins 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 102000003669 Antiporters Human genes 0.000 description 1
- 108090000084 Antiporters Proteins 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical group [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 108091006146 Channels Proteins 0.000 description 1
- 235000019743 Choline chloride Nutrition 0.000 description 1
- 239000003109 Disodium ethylene diamine tetraacetate Substances 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 102000018899 Glutamate Receptors Human genes 0.000 description 1
- 108010027915 Glutamate Receptors Proteins 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 102000004310 Ion Channels Human genes 0.000 description 1
- 108090000862 Ion Channels Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 108010049586 Norepinephrine Plasma Membrane Transport Proteins Proteins 0.000 description 1
- 108700023400 Platelet-activating factor receptors Proteins 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 108091006629 SLC13A2 Proteins 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 108010067973 Valinomycin Proteins 0.000 description 1
- 125000003668 acetyloxy group Chemical group [H]C([H])([H])C(=O)O[*] 0.000 description 1
- 206010000891 acute myocardial infarction Diseases 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 229910052785 arsenic Inorganic materials 0.000 description 1
- RQNWIZPPADIBDY-UHFFFAOYSA-N arsenic atom Chemical compound [As] RQNWIZPPADIBDY-UHFFFAOYSA-N 0.000 description 1
- 125000001231 benzoyloxy group Chemical group C(C1=CC=CC=C1)(=O)O* 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 125000004106 butoxy group Chemical group [*]OC([H])([H])C([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000004744 butyloxycarbonyl group Chemical group 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 210000004720 cerebrum Anatomy 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- SGMZJAMFUVOLNK-UHFFFAOYSA-M choline chloride Chemical compound [Cl-].C[N+](C)(C)CCO SGMZJAMFUVOLNK-UHFFFAOYSA-M 0.000 description 1
- 229960003178 choline chloride Drugs 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- FCFNRCROJUBPLU-UHFFFAOYSA-N compound M126 Natural products CC(C)C1NC(=O)C(C)OC(=O)C(C(C)C)NC(=O)C(C(C)C)OC(=O)C(C(C)C)NC(=O)C(C)OC(=O)C(C(C)C)NC(=O)C(C(C)C)OC(=O)C(C(C)C)NC(=O)C(C)OC(=O)C(C(C)C)NC(=O)C(C(C)C)OC1=O FCFNRCROJUBPLU-UHFFFAOYSA-N 0.000 description 1
- 125000002933 cyclohexyloxy group Chemical group C1(CCCCC1)O* 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 125000003700 epoxy group Chemical group 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 230000014509 gene expression Effects 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000003707 hexyloxy group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])O* 0.000 description 1
- 125000005935 hexyloxycarbonyl group Chemical group 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 125000002510 isobutoxy group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])O* 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000005929 isobutyloxycarbonyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])OC(*)=O 0.000 description 1
- 125000005921 isopentoxy group Chemical group 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000005932 isopentyloxycarbonyl group Chemical group 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 125000005928 isopropyloxycarbonyl group Chemical group [H]C([H])([H])C([H])(OC(*)=O)C([H])([H])[H] 0.000 description 1
- 150000002541 isothioureas Chemical class 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- WGIKEBHIKKWJLG-UHFFFAOYSA-N methanesulfonic acid;2-[4-[(4-nitrophenyl)methoxy]phenyl]ethyl carbamimidothioate Chemical compound CS(O)(=O)=O.C1=CC(CCSC(=N)N)=CC=C1OCC1=CC=C([N+]([O-])=O)C=C1 WGIKEBHIKKWJLG-UHFFFAOYSA-N 0.000 description 1
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 1
- 230000003228 microsomal effect Effects 0.000 description 1
- 210000002464 muscle smooth vascular Anatomy 0.000 description 1
- 125000005484 neopentoxy group Chemical group 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000005933 neopentyloxycarbonyl group Chemical group 0.000 description 1
- 201000009925 nephrosclerosis Diseases 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 235000021590 normal diet Nutrition 0.000 description 1
- UZGLIIJVICEWHF-UHFFFAOYSA-N octogen Chemical group [O-][N+](=O)N1CN([N+]([O-])=O)CN([N+]([O-])=O)CN([N+]([O-])=O)C1 UZGLIIJVICEWHF-UHFFFAOYSA-N 0.000 description 1
- 125000004115 pentoxy group Chemical group [*]OC([H])([H])C([H])([H])C([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 125000001148 pentyloxycarbonyl group Chemical group 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 102000030769 platelet activating factor receptor Human genes 0.000 description 1
- 208000030761 polycystic kidney disease Diseases 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000004742 propyloxycarbonyl group Chemical group 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000023718 relaxation of cardiac muscle Effects 0.000 description 1
- 230000033904 relaxation of vascular smooth muscle Effects 0.000 description 1
- 230000008085 renal dysfunction Effects 0.000 description 1
- 230000008663 renal system process Effects 0.000 description 1
- 230000010410 reperfusion Effects 0.000 description 1
- 210000001908 sarcoplasmic reticulum Anatomy 0.000 description 1
- 125000005920 sec-butoxy group Chemical group 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 125000005930 sec-butyloxycarbonyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(OC(*)=O)C([H])([H])[H] 0.000 description 1
- 125000003548 sec-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 125000004213 tert-butoxy group Chemical group [H]C([H])([H])C(O*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000005922 tert-pentoxy group Chemical group 0.000 description 1
- 125000001973 tert-pentyl group Chemical group [H]C([H])([H])C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000005934 tert-pentyloxycarbonyl group Chemical group 0.000 description 1
- 125000004149 thio group Chemical group *S* 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- FCFNRCROJUBPLU-DNDCDFAISA-N valinomycin Chemical compound CC(C)[C@@H]1NC(=O)[C@H](C)OC(=O)[C@@H](C(C)C)NC(=O)[C@@H](C(C)C)OC(=O)[C@H](C(C)C)NC(=O)[C@H](C)OC(=O)[C@@H](C(C)C)NC(=O)[C@@H](C(C)C)OC(=O)[C@H](C(C)C)NC(=O)[C@H](C)OC(=O)[C@@H](C(C)C)NC(=O)[C@@H](C(C)C)OC1=O FCFNRCROJUBPLU-DNDCDFAISA-N 0.000 description 1
- 230000009278 visceral effect Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/075—Ethers or acetals
- A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
- A61K31/09—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon having two or more such linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
Definitions
- the present invention relates to a novel therapeutic agent for chronic kidney disease.
- NCX Na + / Ca 2 + exchange transporter
- the Na + / Ca 2 + exchange transporter plays an important role in the contraction and relaxation of cardiac muscle and vascular smooth muscle (Aim. Rev. Physiol. 52: 467 (1990)).
- NCX Na + / Ca 2 + exchange transporter
- NCX1 protein is expressed in large amounts in the brain, heart, and kidney
- NCX2 protein is mainly expressed in the brain and small amounts in visceral smooth muscle
- NCX3 protein is mainly expressed in the brain and small amounts in skeletal muscle.
- NCX inhibitors isothiourea derivatives such as (2- [2- [4 [nitrobenzyloxy] henyl] ethyD isothi o-ure amethanesul fonate) (KB-R7943) and 2- [4-[(2,5 -difluorop henyl) methoxy] phenoxy] -5-ethoxyani 1 ine (SEA0400) and other phenoxyaniline derivatives.
- K-BR7943 is an acute myocardial infarction model and a brain and kidney ischemia / reperfusion model. Has been confirmed (J. Pharmacol. Exp. Ther. Vol. 296, 412 (2001)). However, no application of NCX inhibitors to the treatment of chronic kidney disease has been reported. Disclosure of the invention
- the present inventors measured the NCX inhibitory activity of K-BR7943, SEA0400, and the like using Na + / Ca 2 + exchange transporter (NCX) prepared from brain, heart, and kidney.
- NCX Na + / Ca 2 + exchange transporter
- phenoxyaniline derivatives and phenoxypyridine derivatives such as SEA0400 It was found to selectively inhibit heart and kidney-derived NCX as compared to NCX from 03 00675.
- the present inventors aimed to elucidate the relationship between NCX1 and disease 'treatment, and selected the NCX1 selective model for various disease models (such as chronic renal failure Z glomerulosclerosis model and diabetic lad). Investigations using inhibitors found that inhibiting NCX1 was effective for renal protection in chronic renal failure, glomerulosclerosis, and diabetic nephropathy, and completed the present invention. .
- the present invention is a therapeutic agent for chronic kidney disease, comprising a compound that inhibits Na + / Ca2 + exchange transporter 1 as an active ingredient.
- R 1 represents a hydrogen atom or ( ⁇ -( 6 alkoxy group)
- R 2 represents a halogen atom or a nitro group
- R 3 represents a hydrogen atom or a halogen atom.
- the compound that inhibits NCX1 is a compound that inhibits kidney-derived NCX1! There is no particular limitation as long as the compound is harmful. However, in the test described below (Reference Example 3), 50 Those that inhibit by more than% are preferred. Further, a compound that specifically inhibits NCX is preferred for the purpose of preventing side effects.
- a compound that specifically inhibits NCX1 refers to a compound that hardly inhibits other receptors, channels and transporters at a concentration that inhibits NCX1, specifically, for example, Ca 2+ at a concentration of 3 M.
- Ad renergic receptor Glutamate receptor, Bradykinin receptor, LTB4 receptor and PAF receptor are preferably not inhibited by 50% or more.
- Examples of compounds that specifically inhibit NCX1 include phenoxyaniline derivatives and phenoxypyridine derivatives.
- R 4 , R 5 and R 6 are the same or different and represent a hydrogen atom or a halogen atom, and X is
- R 7 represents a hydrogen atom, a substituted or unsubstituted alkyl group or a substituted or unsubstituted alkoxy group
- Z represents a nitro group
- amino group or HC ( I) represents a CH 2 R 8 group
- R 8 is a hydrogen atom, a substituted or unsubstituted ⁇ alkyl group, a substituted or unsubstituted ( ⁇ ⁇ (: 6 alkoxy group, halogen atom, hydroxy group, C 2 -C 7 Acyloxy group, NR 9 R I () or
- R 9 and R 1 11 are the same or different and each a hydrogen atom, a substituted or unsubstituted C, ⁇ (; s alkyl group, N- methyl-4 shows the Piperijiniru group, R 1 1 is hydrogen atom, arsenic Dorokishi group Or a C 2 -C 7 alkoxycarbonyl group, Y represents a methylene group, an epoxy group, a thio group or an NR 12 group, and n represents an integer of 1 to 4.
- R 12 represents a hydrogen atom, A substituted or unsubstituted alkyl group or a substituted or unsubstituted phenyl group.] Or a pharmaceutically acceptable salt thereof.
- R 1 represents a hydrogen atom or an alkoxy group
- R 2 represents a halogen atom or a nitro group
- R 3 represents a hydrogen atom or an octogen atom.
- ⁇ (: 6 alkoxy group means a linear or branched alkoxy group having 1 to 6 carbon atoms, for example, methoxy group, ethoxy group, propoxy group, Propoxy group, butoxy group, isobutoxy group, sec-butoxy group, tert-butoxy group, pentyloxy group, isopentyloxy group, neopentyloxy group, tert-pentyloxy group, 1-methylbutoxy group, 2-methylbutoxy group , 1, 2— Examples include a dimethylpropoxy group, a hexyloxy group, and an isohexyloxy group.
- Substituents-Substituents of the alkoxy group include a chloro group, a fluoro group, a nitro group, an amino group, a dimethylamino group, a carbonyl group, a methoxycarbonyl group, an ethoxycarbonyl group, a phenyl group, a hydroxy group, a cyano group, And a lubamoyl group.
- the halogen atom means a fluorine atom, a chlorine atom, a bromine atom or an iodine atom.
- a C t -C 6 alkyl group means a straight-chain or branched alkyl group having 1 to 6 carbon atoms, such as a methyl group, an ethyl group, a propyl group, an isopropyl group, a butyl group, and an isobutyl group.
- Substitution ⁇ (:
- the substituents of the 6 alkyl groups include, for example, chloro, fluoro, nitro, amino, dimethylamino, carboxyl, methoxycarbonyl, ethoxycarponyl, phenyl, methoxy, ethoxy , A hydroxy group, a cyano group, and a carbamoyl group.
- the C 2 -C 7 acyloxy group means a linear or branched acyloxy group having 2 to 7 carbon atoms, and the acyl moiety may be cyclic or may contain an aromatic group.
- an acetoxy group, a propionyloxy group, an isopropionyloxy group, a cyclohexyloxy group, a benzoyloxy group and the like can be mentioned.
- the C 2 -C 7 alkoxycarbonyl Cal Poni group means a straight or branched ⁇ Rukokishikarubo two Le group having a carbon number of 2-7, an alkoxyl moiety may be cyclic, comprise an aromatic group May be.
- Examples of the substituent of the substituted phenyl group include a chloro group, a fluoro group, a nitro group, an amino group, a dimethylamino group, a lipoxidyl group, a methoxycarbonyl group, an ethoxycarbonyl group, a methyl group, an ethyl group, a methoxy group, an ethoxy group, and a hydroxy group.
- the compound is a compound that more strongly inhibits NCX1 than NCX2 and NCX3.
- the compound is a compound that more strongly inhibits NCX1 than NCX2 and NCX3.
- IC 50 (from renal cortex)
- IC 50 (from myocardium)
- the compounds represented by the formulas (1) and (2) are described in WO 98/43943, WO 99/20598, JP-A-10-265460, JP-A-10-218844, JP-A-11-49752, and JP-A-11-19752. According to the manufacturing method described in 92454 Can be synthesized.
- the therapeutic agent for chronic kidney disease refers to chronic renal disease including chronic renal failure, renal glomerulosclerosis, diabetic nephropathy, renal sclerosis, chronic nephritis, chronic glomerulonephritis, polycystic kidney disease and the like. It refers to a therapeutic agent for diseases that lower the renal physiology, and has excellent renal protection, such as reducing urinary protein and albumin. .
- the therapeutic agent of the present invention is orally or parenterally prepared in an appropriate pharmaceutical composition form (tablets, pills, capsules, granules, dry syrups, injections, etc.) using known carriers, diluents and the like as appropriate.
- an appropriate pharmaceutical composition form tablettes, pills, capsules, granules, dry syrups, injections, etc.
- Solid additives are manufactured using various additives, for example, excipients, disintegrants, binders, lubricants, and coating bases, and are manufactured by stirring granulation, fluidized bed granulation, and crushing granulation. it can.
- an antioxidant if necessary, an antioxidant, a coating agent, a coloring agent, a flavoring agent, a surfactant, a plasticizer and the like can be added.
- the dosage of the active ingredient of the medicament of the present invention varies depending on the age, body weight, administration form and the like, but it is usually 0.1 to 1000 mg / day for an adult, which is administered once or several times a day.
- the present invention will be described using formulation examples, test examples, and the like, but the present invention is not limited to these test examples and the like.
- Microsomes (1.5 mg / ml) obtained from rat (8-week-old) cerebrum were pretreated with a buffer containing 160 mM NaC1 and Na was loaded into the membrane vesicles. After inducing 4 5 Ca uptake was diluted 50-fold with the suspension 20 ⁇ ⁇ 4 5 CaCl 2 containing buffer, the reaction is stopped by dilution with the buffer i (0), immediately onto a nitrocellulose membrane Collect membrane vesicles. Thereafter, the 4 5 Ca membrane vesicles was determined by liquid scintillation Isseki of the Act. The measurement of the Na + / Ca 2 + exchange activity in the cerebral microsomes was performed according to the method of J. Biol. Chem. Vol. 257, pp. 5111 (1982). Measurement of Reference Example 2 I j myocardial membrane vesicles Na + / Ca 2 + antiporter
- Canine myocardial vesicles (0.5 mg / ml) were prepared according to Methods enzymology volume 157, page 85 (1988).
- the suspension was suspended in solution A (20 mM M0PS-Tris (pH 7.4), 160 mM NaCl or KCl) and allowed to stand at room temperature for about 1 hour to load Na or K into the vesicles. .
- the suspension was diluted 50-fold with a buffer containing 20 ⁇ M 45 CaCl 2 to induce 45 Ca uptake, and then diluted with a buffer (0 ° C) to stop the reaction.
- Membrane vesicles were collected. Thereafter, 45 Ca in the membrane vesicles was quantified by the liquid scintillation overnight method.
- the Na + / Ca 2 + exchange activity was evaluated as a value obtained by subtracting the value obtained when K was loaded from the value obtained when Na was sipped.
- the measurement of the Na + / Ca exchange activity in canine myocardial vesicles was performed according to the method of J. Biol. Chem., 257, 5111 (1982).
- Reference Example 3 Preparation of BLMV (basolateral membrane vesicles) from rat kidney cortex and method for measuring Na + / Ca 2 + exchange activity
- sucrose buf fer After removing the kidney from the rat, put it in ice-cold sucrose buffer (0.25 mM sucrose, 0. ImM PMSF, lOmM Tris-HCl (pH 7.6)), remove the coating, and isolate the isolated cortex in sucrose buf fer Cut finely. After homogenizing with a dounce homogenizer, homogenizing was performed with a polytron homogenizer. Then, the supernatant was collected by centrifugation at 2500 g for 15 minutes. Further, the mixture was centrifuged at 24000 g for 20 minutes to recover a white fluffy portion of the pellet. Further, sucrose buf fer was added, and the mixture was homogenized with a dounce homogenizer.
- the mixture was centrifuged at 30,000 g for 35 minutes to collect the middle layer. Thereafter, buf fer (100 mM KCl, 100 mM mannitol, 5 mM HEPES-Tris (pH 7.4)) was added, and the mixture was centrifuged at 34000 g for 30 minutes to collect a loose white pellet (BLMV). After suspending in KC mannitol buf fer, the precipitate was recovered by centrifugation at 34000 g for 30 min and used for activity measurement.
- buf fer 100 mM KCl, 100 mM mannitol, 5 mM HEPES-Tris (pH 7.4)
- the BLMV suspension e xternal medium (lOOmM choline chloride, 40mM KCI, ImM MgS0 4, lOmM glucose, 5mM HEPES-Tris (pH7.4), 25uM valinomycin, lOuM CaCl 2, lmCi / 1 45 CaCl 2) at 2 Incorporation was started by diluting 0-fold. After reacting at 25 ° C for a certain period of time, stop the reaction by adding 2 ml of stop solution (ice-co Id 150 mM KCI), and immediately filter through an ultrafiltration membrane (0.45 ⁇ m nitrocellulose filter) to filter BLMV. Recovered above. Then, after washing twice with 2 ml stop solution, 45 Ca incorporated into BLMV was quantified by the liquid scintillation overnight method.
- stop solution ice-co Id 150 mM KCI
- Group I Oral administration of DaM-R + 4% NaCl diet + solvent (twice a day)
- the urinary protein excretion 6 weeks after the start of the study was 23 ⁇ 2 mg / day in group I and 144 ⁇ 11 mg / day in group ⁇ , but 91 ⁇ 12 mg / day in the SEA0400 administration group (m group). The day was significantly lower than that of the vehicle-administered group (group ⁇ ).
- Urinary albumin excretion was 1 mg / day in group I, 2 soils, and 109 ⁇ 14 mg / da in group ⁇ , but 58 ⁇ 8 mg / day in the SEA0400 administration group (E [group]). The value was significantly lower than that of the vehicle-administered group (group I).
- ZSF-1 is a spontaneously diabetic rat and is known to cause renal dysfunction (Renal Failure Vol. 22, No. 4, pp. 387-406, 2000).
- Group I Oral administration of ZSF-1 / lean + solvent (twice a day)
- Group IV ZSF-1 + SEA0400 3 mg / kg orally (twice a day)
- Group V ZSF-1 + SEA0400 10 mg / kg orally (twice daily)
- Solvent SEA0400 is orally administered twice a day (8:30 to 10:30 for the first dose and 16:30 to 18:30 for the second dose) for 8 consecutive weeks. Eight weeks after the start of administration, each rat was placed in a metabolic cage, urine was collected, and the amount of protein and albumin in the urine was measured to observe the effect on renal function. Urine protein and albumin levels were measured using a Hitachi automatic analyzer 7060 according to the description in the above-mentioned literature.
- the urinary protein excretion 8 weeks after the start of the test was as follows: Group I: 14 ⁇ 1 mg / day, Group I: 58 ⁇ 9 mg / day Group I: 40 ⁇ 8 mg / day, Group IV: 37 ⁇ 7 mg / day Day, group: 29 ⁇ 5 mg / da, and the S EA0400 10 mg / kg administration group (group V) was significantly lower than the vehicle administration group (group)).
- Urinary albumin excretion was as follows: Group I: 1 ⁇ 0.1 mg / day, Group 28: 28 ⁇ 5 mg / day IE group: 20 ⁇ 5 mg / day, Group IV: 17 ⁇ 5 mg / day, Group V : 9 ⁇ 2 mg / day, and the SEA0400 10 mg / kg administration group (Group V) was significantly lower than the solvent administration group (Group)).
- SEA0400 significantly suppressed the increase in urinary protein and albumin excretion observed in spontaneously diabetic rats, and showed a renal protective effect.
- the present invention it is possible to provide a therapeutic agent for chronic kidney disease based on a novel mechanism of action, and it is useful for treatment and prevention of chronic kidney disease with few side effects.
Description
Claims
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP03731835A EP1475103A4 (en) | 2002-01-25 | 2003-01-24 | MEANS FOR THE TREATMENT OF CHRONIC KIDNEY DISEASES |
US10/502,547 US20050203189A1 (en) | 2002-01-25 | 2003-01-24 | Remedies for chronic kidney diseases |
JP2003561642A JPWO2003061700A1 (ja) | 2002-01-25 | 2003-01-24 | 慢性腎疾患治療薬 |
HK05106033A HK1073257A1 (en) | 2002-01-25 | 2005-07-15 | Remedies for chronic kidney diseases |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2002017474 | 2002-01-25 | ||
JP2002-17474 | 2002-01-25 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2003061700A1 true WO2003061700A1 (fr) | 2003-07-31 |
Family
ID=27606170
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2003/000675 WO2003061700A1 (fr) | 2002-01-25 | 2003-01-24 | Medicaments servant au traitement de nephropathies chroniques |
Country Status (6)
Country | Link |
---|---|
US (1) | US20050203189A1 (ja) |
EP (1) | EP1475103A4 (ja) |
JP (1) | JPWO2003061700A1 (ja) |
CN (1) | CN1268395C (ja) |
HK (1) | HK1073257A1 (ja) |
WO (1) | WO2003061700A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2008189592A (ja) * | 2007-02-05 | 2008-08-21 | Toa Eiyo Ltd | ブトキシアニリン誘導体 |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108939075A (zh) * | 2018-07-26 | 2018-12-07 | 陕西师范大学 | Ncx1基因作为治疗呼吸暂停综合症的药物干预靶点的应用 |
Citations (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH10218844A (ja) * | 1997-02-13 | 1998-08-18 | Taisho Pharmaceut Co Ltd | 2−フェノキシアニリン誘導体 |
JPH10245336A (ja) * | 1997-03-03 | 1998-09-14 | Taisho Pharmaceut Co Ltd | Na/Ca交換系阻害剤 |
JPH1149752A (ja) * | 1997-08-05 | 1999-02-23 | Taisho Pharmaceut Co Ltd | フェノキシピリジン誘導体 |
JPH1192454A (ja) * | 1997-09-17 | 1999-04-06 | Taisho Pharmaceut Co Ltd | フェノキシピリジン誘導体 |
JPH11302235A (ja) * | 1998-04-15 | 1999-11-02 | Taisho Pharmaceut Co Ltd | フェノキシアルキルアミン誘導体 |
EP0978506A1 (en) * | 1997-03-27 | 2000-02-09 | Taisho Pharmaceutical Co., Ltd | 2-phenoxyaniline derivatives |
EP1031556A1 (en) * | 1997-10-20 | 2000-08-30 | Taisho Pharmaceutical Co., Ltd | 2-phenoxyaniline derivatives |
JP2000355537A (ja) * | 1999-04-16 | 2000-12-26 | Taisho Pharmaceut Co Ltd | Na+/Ca2+交換系阻害剤 |
WO2002032883A1 (fr) * | 2000-10-18 | 2002-04-25 | Senju Pharmaceutical Co., Ltd. | Nouveau derive de 4-benzyloxyphenyle et utilisation de ce derive |
WO2002034250A1 (en) * | 2000-10-26 | 2002-05-02 | Taisho Pharmaceutical Co., Ltd. | Fat emulsions |
US6423705B1 (en) * | 2001-01-25 | 2002-07-23 | Pfizer Inc. | Combination therapy |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9027203D0 (en) * | 1990-12-14 | 1991-04-24 | Eev Ltd | Firing arrangements |
JPH0995455A (ja) * | 1995-09-29 | 1997-04-08 | Sumitomo Pharmaceut Co Ltd | 腎機能改善剤 |
SG87052A1 (en) * | 1996-02-20 | 2002-03-19 | Bristol Myers Squibb Co | Pinacol ester intermediates useful for the preparation of biphenyl isoxazole sulfonamides |
US6196131B1 (en) * | 1998-07-08 | 2001-03-06 | Ronald A. Yanda | Shock tube initiator tip encased in a non-conductive material |
US6933104B1 (en) * | 1999-04-23 | 2005-08-23 | Shiva Biomedical, Llc | Diagnosis and treatment of human kidney diseases |
-
2003
- 2003-01-24 EP EP03731835A patent/EP1475103A4/en not_active Withdrawn
- 2003-01-24 US US10/502,547 patent/US20050203189A1/en not_active Abandoned
- 2003-01-24 CN CNB038025914A patent/CN1268395C/zh not_active Expired - Fee Related
- 2003-01-24 WO PCT/JP2003/000675 patent/WO2003061700A1/ja active Application Filing
- 2003-01-24 JP JP2003561642A patent/JPWO2003061700A1/ja active Pending
-
2005
- 2005-07-15 HK HK05106033A patent/HK1073257A1/xx not_active IP Right Cessation
Patent Citations (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH10218844A (ja) * | 1997-02-13 | 1998-08-18 | Taisho Pharmaceut Co Ltd | 2−フェノキシアニリン誘導体 |
JPH10245336A (ja) * | 1997-03-03 | 1998-09-14 | Taisho Pharmaceut Co Ltd | Na/Ca交換系阻害剤 |
EP0978506A1 (en) * | 1997-03-27 | 2000-02-09 | Taisho Pharmaceutical Co., Ltd | 2-phenoxyaniline derivatives |
JPH1149752A (ja) * | 1997-08-05 | 1999-02-23 | Taisho Pharmaceut Co Ltd | フェノキシピリジン誘導体 |
JPH1192454A (ja) * | 1997-09-17 | 1999-04-06 | Taisho Pharmaceut Co Ltd | フェノキシピリジン誘導体 |
EP1031556A1 (en) * | 1997-10-20 | 2000-08-30 | Taisho Pharmaceutical Co., Ltd | 2-phenoxyaniline derivatives |
JPH11302235A (ja) * | 1998-04-15 | 1999-11-02 | Taisho Pharmaceut Co Ltd | フェノキシアルキルアミン誘導体 |
JP2000355537A (ja) * | 1999-04-16 | 2000-12-26 | Taisho Pharmaceut Co Ltd | Na+/Ca2+交換系阻害剤 |
WO2002032883A1 (fr) * | 2000-10-18 | 2002-04-25 | Senju Pharmaceutical Co., Ltd. | Nouveau derive de 4-benzyloxyphenyle et utilisation de ce derive |
WO2002034250A1 (en) * | 2000-10-26 | 2002-05-02 | Taisho Pharmaceutical Co., Ltd. | Fat emulsions |
US6423705B1 (en) * | 2001-01-25 | 2002-07-23 | Pfizer Inc. | Combination therapy |
Non-Patent Citations (5)
Title |
---|
See also references of EP1475103A4 * |
TAKAHIRO IWAMOTO ET AL.: "Idenshi kaihen mouse o mochiita Na+/Ca2+ kokan yusotai no kino kaiseki to soyaku", FOLIA PHARMACOLOGICA JAPONICA, no. 1, 10 November 2002 (2002-11-10), pages 91 - 93, XP002967653 * |
TAKAHIRO IWAMOTO ET AL.: "Kitai sareru calcium chiryoyaku <Na+/Ca2+kokantai sogaiyaku>", CLINICAL CALCIUM, vol. 11, no. 6, 2001, pages 784 - 789, XP002967650 * |
YAMASHITA JUNJI ET AL.: "Pre- or post-ischemic treatment with a novel Na+/Ca2+ exchange inhibitor, KB-R7943, shows renal protective effects in rats with ischemic acute renal failure", JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, vol. 296, no. 2, 2001, pages 412 - 419, XP002967651 * |
YASUO MATSUMURA: "Jin kyoketsu saikanryu shogai: Hassho, shinten kiko to shogai kaizenyaku", PHARMACOMETRICS, vol. 60, no. 4, 2001, pages 103 - 106, XP002967652 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2008189592A (ja) * | 2007-02-05 | 2008-08-21 | Toa Eiyo Ltd | ブトキシアニリン誘導体 |
Also Published As
Publication number | Publication date |
---|---|
JPWO2003061700A1 (ja) | 2005-05-19 |
EP1475103A4 (en) | 2007-11-07 |
US20050203189A1 (en) | 2005-09-15 |
HK1073257A1 (en) | 2005-09-30 |
EP1475103A1 (en) | 2004-11-10 |
CN1268395C (zh) | 2006-08-09 |
CN1620312A (zh) | 2005-05-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2002520274A (ja) | バルサルタンとカルシウムチャンネルブロッカーの抗高血圧組合わせ | |
JP2011068669A (ja) | Gerdの治療のためのmglur5アンタゴニストの使用 | |
CZ298469B6 (cs) | Farmaceutický prostredek obsahující 5-[4-/2-(N-methyl-N-(2-pyridyl)amino)ethoxy/benzyl]thiazolidin-2,4-dion a metformin, a lécivo pro lécení diabetesmellitus | |
JP2009537565A (ja) | R(+)およびs(−)プラミペキソール組成とそれを利用する方法 | |
JP5788527B2 (ja) | キナーゼ阻害剤の副作用低減剤 | |
PL202906B1 (pl) | Zastosowanie antagonisty mGluR5 | |
EP0077723B1 (fr) | Composition pharmaceutique à action antagoniste périphérique des narcotiques | |
CN101878030A (zh) | 用于治疗免疫性和炎性疾病和病症的组合物和方法 | |
TWI327468B (en) | Pharmaceutical composition | |
CN108367016B (zh) | 用于治疗异位脂肪堆积的a3腺苷受体配体 | |
WO2003061700A1 (fr) | Medicaments servant au traitement de nephropathies chroniques | |
JPH03215426A (ja) | 血糖上昇抑制剤 | |
JP2009102399A (ja) | 利尿機能および腎機能を回復するためのアデノシンa1レセプターアンタゴニスト含有組成物および方法 | |
JPH07145166A (ja) | 4−アミノ−1−(2−ピリジル)ピペリジン誘導体の利用 | |
JP3598116B2 (ja) | 遅発性ジスキネジアの治療用医薬組成物とその利用 | |
JPH05247025A (ja) | 神経保護的作用を有する組み合わせ調製物 | |
EP2157089A1 (en) | The therapeutic uses of imidazol-5-carboxylic acid derivatives | |
WO2003068263A1 (fr) | Remede contre l'hypertension | |
JP2013526503A (ja) | キサンチンオキシダーゼ阻害剤とアンジオテンシンii受容体アンタゴニストとの合剤およびその使用 | |
Conti et al. | Selective agonists and antagonists for kainate receptors | |
JPH0665203A (ja) | ピペラジンのヘテロ環誘導体 | |
US20040138207A1 (en) | Antitumor agents | |
JPH05194217A (ja) | 抗高血圧組み合わせ医薬 | |
KR100697097B1 (ko) | 당뇨병 예방 또는 치료용 약학 조성물 | |
US4419367A (en) | Stimulant |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2003561642 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 20038025914 Country of ref document: CN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2003731835 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2003731835 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10502547 Country of ref document: US |